K-numberK240788
Device nameUltrasound Stimulator
ApplicantJkh Health Co., Ltd.
Product codeIMI
Device classClass II
Decision dateJun 4, 2025
DecisionSubstantially Equivalent
Regulation890.5300
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Ultrasound Stimulator is a portable, rechargeable prescription device that applies ultrasonic energy to generate deep heat within body tissues. It is used in home or clinical settings to treat pain, muscle spasms, joint contractures, and related conditions, operated for up to 30 minutes per cycle (maximum 4 cycles) by or under direction of a medical professional.

Technological characteristics

The device operates at 1.5 MHz ± 10% frequency with a maximum output power of 0.60 W ± 20% and temporal average power of 0.60 W ± 20%. It features piezoelectric ultrasound generation in continuous wave mode (100% duty cycle), supports 1 or 2 applicators with 3.9 cm² effective radiating area, includes software/firmware microprocessor control, automatic shut-off and no-load trip functions, and complies with IEC 60601-2-5 for thermal safety with a maximum patient contact surface temperature of 43°C.

Test standards cited

Compliance verified with ANSI AAMI ES60601-1, IEC 60601-1-2, IEC 60601-2-5, ISO 10993-5, ISO 10993-10, IEC 60601-1-6, and IEC 60601-1-11. Testing included power output evaluation, electrical safety and EMC evaluation, thermal safety evaluation, biocompatibility evaluation, and software verification per FDA guidance for medical device software.

Substantial equivalence argument

The subject device is identical or similar to predicate devices (ManaSport+ and sam 2.0) across all critical parameters: same 1.5 MHz frequency, identical 0.60 W output power and continuous wave mode, same indications for use treating pain and muscle spasms, identical prescription classification, equivalent cooling/temperature management despite a 30-minute cycle limit (versus 20 or 240 minutes in predicates), and compliance with the same voluntary standards including IEC 60601-2-5. The shorter treatment time and associated lower temperature rise do not create new safety or effectiveness issues, supported by thermal testing demonstrating no adverse impact.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →